Editing Personalized Medicine (section)

== <span style="color: #FFFFFF;">Understanding</span> ==
'''The population-average problem''': Most medical guidelines are derived from clinical trials and applied uniformly. A drug showing 30% mean benefit in a trial hides enormous variability — some patients respond dramatically, others not at all, some are harmed. Personalized medicine seeks to identify which patient is which before prescribing.

'''AI for treatment response prediction''': By training on large cohorts with genomic, molecular, and clinical features linked to treatment outcomes, ML models predict individual treatment response. Examples: predicting which cancer patients will respond to immunotherapy (from TMB, MSI, PD-L1, and gene expression), which psychiatric patients will respond to SSRIs vs. SNRIs (from pharmacogenomic markers), and which hypertensive patients will respond to ACE inhibitors vs. calcium channel blockers (from clinical features).

'''Multi-omics integration''': Any single data type (genomics alone, transcriptomics alone) provides incomplete information. Multi-omics integration — combining data from multiple measurement levels — provides a more complete molecular portrait. ML models (autoencoders for dimensionality reduction, graph neural networks for pathway-level integration, multi-modal transformers) integrate these diverse data types. The challenge: multi-omics datasets are expensive to generate and small (hundreds to thousands of patients), requiring careful regularization.

'''Digital patient twins''': A computational model parameterized by individual patient data (physiology, pharmacokinetics, disease state) that can simulate how the patient will respond to different treatments. Pharmaceutical companies (Dassault Systèmes, Unlearn.ai) use patient digital twins to generate synthetic control arms and predict trial outcomes. Clinical digital twins for oncology simulate tumor growth dynamics to guide treatment timing.

'''Microbiome personalization''': The gut microbiome varies enormously across individuals and influences drug metabolism, immunotherapy response, and disease risk. ML models on microbiome composition data predict: statin response, immunotherapy success (gut microbiome predicts checkpoint inhibitor outcomes), and probiotic intervention benefit.
</div>

<div style="background-color: #8B0000; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">